A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT04516291

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
  • The TIMI Study Group Registry lists this organization as a collaborator
Registry
  • NCT NCT04516291
  • EudraCT 2020-002796-35
Other papers using this trial's data
  • Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 Circulation, 2022-05-03 DOI, PubMed 35369705, PMC9047643 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04516291. Randomized; triple masking; primary purpose treatment. Start 2020-09-28 (actual); primary completion 2021-09-29 (actual). Results posted on 2022-10-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Condition
Dyslipidemias
Condition
Hyperlipidemias
Condition
Hyperlipoproteinemias
Intervention (Drug)
Vupanorsen
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct04516291
Content hash
2353ed1fe09ac86993a00c6ad4e691345e045b2222b54376b916b6bebf9edc00